March 21, 2014 / 6:11 AM / in 4 years

BRIEF-U C B returns global rights to Tozadenant to Biotie

BRUSSELS, March 21 (Reuters) - U C B SA : * UCB returns global rights to Tozadenant to Biotie * Portfolio decision by UCB in light of its pipeline priorities biotie will continue to develop Tozadenant in parkinson’s disease * Tozadenant is scheduled to start the phase 3 development program in 2015. * Decision does not impact ucb’s financial guidance for 2014 * Decision will lead to non-recurring, one-time write-off of UCB’s intangible assets,other related programs,costs of about EUR 40 million

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below